CompoundedGuide
Verification in progress

Thymosin beta-4

Exact form, route, and dosage not yet verified · Also known as: Tβ4

Under review

Thymosin beta-4 is listed in the CompoundedGuide registry with no verified FDA-approved product. FDA lists Thymosin beta-4 among bulk drug substances for use in compounding that may present significant safety risks. Thymosin beta-4 is not on FDA's 503B Bulks List for outsourcing facilities (list checked 2026-07-25). 18 registered ClinicalTrials.gov studies cite Thymosin beta-4 (11 completed, 2 recruiting, 2 terminated, 2 withdrawn, 1 not yet recruiting); registration is not evidence of approval, efficacy, or safety. Identity and regulatory status are pending source collection and editorial review. This is not medical advice.

What we're checking

Is there an FDA-approved product?
Checking Drugs@FDA, Purple Book, Orange Book
What's the compounding status?
Checking FDA 503A/503B pages, Federal Register
Are there safety signals?
Checking FDA warnings, recalls, FAERS
What does the research show?
Checking ClinicalTrials.gov, PubMed

Sources we need

  • identity: FDA/NCATS GSRS or equivalent canonical identity source
  • product status: Drugs@FDA, Purple Book, Orange Book, DailyMed, or applicable primary FDA record
  • compounding status: FDA 503A/503B pages, Federal Register, docket, or applicable final/interim policy
  • safety: FDA safety communication, warning, recall, FAERS signal context, or explicit absence statement
  • evidence: ClinicalTrials.gov and PubMed/primary publication search
  • state or facility: State board or FDA facility record when relevant

Research and evidence

18 registered clinical studies cite Thymosin beta-4. Registration is not evidence of approval, efficacy, or safety.

Browse every trial and publication for Thymosin beta-4 →

Sources checked

Captured from the source and re-checked against it. Not yet editorially reviewed.

For developers
JSON record Markdown Source packet